Neurons grown from migraine patients' stem cells showed abnormal CGRP expression, ion channel dysfunction, and altered excitability — providing a human-based platform to study migraine mechanisms.
CGRP dysregulated in patient neuronsGlutamatergic neurons derived from migraine patients' own stem cells showed abnormal expression of CGRP — the same peptide targeted by today's most effective migraine drugs — along with ion channel dysfunction and altered pain signaling.
What the researchers found
Glutamatergic neurons derived from migraine patient iPSCs showed functional abnormalities compared to healthy controls. Ion channel dysfunction was observed in sodium and potassium channel function via patch-clamp recordings. Expression of migraine-associated molecules was altered, including CGRP (calcitonin gene-related peptide), P2RX3 (a pain receptor), and c-Fos (a marker of neuronal activation).
These findings collectively suggest that intrinsic neuronal dysfunction — present even in lab-grown cells outside the body — may contribute to migraine pathology. The study establishes the feasibility of using iPSC-derived neurons as a human-specific migraine research model.
Why it matters
Current migraine research relies heavily on animal models that can't capture the human-specific genetics and biology driving migraines. This iPSC approach creates neurons that carry the patient's actual genetic background, enabling researchers to study migraine mechanisms in a way that's directly relevant to the human disease. The finding that CGRP — the target of today's most effective migraine drugs — is abnormally expressed in these patient-derived neurons validates the model and could eventually enable testing of personalized treatments.
How the study worked
Induced pluripotent stem cells (iPSCs) were generated from both migraine patients and healthy controls, then differentiated into glutamatergic neurons. Electrophysiological properties were measured using whole-cell patch-clamp recordings to assess sodium and potassium channel function. Expression of migraine-associated molecules (CGRP, P2RX3, c-Fos) was evaluated using immunofluorescence staining and quantitative real-time PCR.
What this study cannot tell us
This is a proof-of-concept study with preliminary findings. The abstract does not specify the number of patient and control iPSC lines used, which is critical for a field prone to line-to-line variability. iPSC-derived neurons may not fully recapitulate the complexity of neurons in the intact brain, including their connections with other cell types and the trigeminal vascular system central to migraine. The in vitro environment lacks the hormonal, vascular, and immune system influences that contribute to migraine attacks.
How to read the evidence
This is a proof-of-concept laboratory study demonstrating feasibility of an iPSC-based migraine model. While the electrophysiology and molecular analyses are rigorous, the study is preliminary — the number of patient lines, replication, and clinical correlation are not detailed in the abstract. The findings are hypothesis-generating and establish a platform rather than definitive conclusions.
When this study was published
Published in 2025, this study represents the cutting edge of combining stem cell technology with migraine neuroscience. iPSC-derived neuronal models for neurological diseases are a rapidly advancing field.
The bigger picture
This study represents the intersection of two major trends: stem cell technology and CGRP-targeted migraine therapeutics. While anti-CGRP antibodies and gepants have transformed migraine treatment, not all patients respond equally — and understanding why requires human neuronal models. iPSC-derived neurons could serve as a testing platform for drug screening, allowing researchers to predict which patients will respond to which treatments. This aligns with the broader precision medicine movement in neurology.
Questions still open
- Can this iPSC model predict which migraine patients will respond to anti-CGRP therapies versus other treatment approaches?
- Do the ion channel abnormalities seen in these neurons correspond to specific genetic variants known to increase migraine risk?
- Could this platform be used to screen novel migraine drugs before clinical trials, reducing the high failure rate in headache drug development?
Common questions
How can lab-grown neurons help us understand migraines?
What does CGRP have to do with this research?
Read the original research
Exploring the potential pathogenesis of migraine using glutamatergic neuron models derived from induced pluripotent stem cells (iPSCs) of migraine patients.
Brain research, 1866, 149938
Citation
Xu, Yueyue; Yao, Yitian; Sun, Li; Chen, Li; Li, Chenyang; Wang, Wenyuan; Yang, Jiajun. (2025). Exploring the potential pathogenesis of migraine using glutamatergic neuron models derived from induced pluripotent stem cells (iPSCs) of migraine patients.. Brain research, 1866, 149938. https://doi.org/10.1016/j.brainres.2025.149938